Dr David Atkins, Chief Executive Officer of Congenica, has joined the National Genomics Board as the BioIndustry Association (BIA)’s SME representative.

The Board brings together senior decision makers from government, the NHS, academia and industry to advise the UK Government on its national genomics strategy, Genome UK. Dr Atkins’ appointment to the Board means that the voice of genomic start-ups and SMEs will be heard at the highest levels of government.

Dr David Atkins, Chief Executive Officer, Congenica, said:

“The National Genomics Board will play a crucial role in implementing the vision outlined in Genome UK. This strategy is based upon driving innovation, attracting investment, and delivering genomics-driven healthcare to patients to accelerate the diagnostic process and ultimately improve treatments. It is an honour to join such an esteemed group as the BIA’s representative and I look forward to working together as we further advance the UK’s position as a global genomics leader and incorporate clinical genomics into routine diagnostics.”

Steve Bates OBE, Chief Executive of the BIA, said: “The UK is a world-leader in genomics as demonstrated by the great work in sequencing genetic variants of SARS-CoV-2. The role of SMEs in driving genomic innovation cannot be understated and I am delighted that David is joining the National Genomics Board. As the Chief Executive of a successful UK-grown genomic SME, a BIA Board Member, and an active member of the BIA’s Genomics Advisory Committee, David is uniquely qualified to represent the BIA’s genomics community to the Board. We look forward to working with David and the rest of the Board to build a thriving genomics industry to benefit NHS patients and as we rebuild our economy from COVID-19.”